Daunorubicin/cytarabine

From Wikipedia, the free encyclopedia

Daunorubicin/cytarabine
Cytarabin.svg
Cytarabine
Daunorubicin2DACS.svg
Daunorubicin
Combination of
DaunorubicinAnthracycline
CytarabineAntimetabolite
Clinical data
Trade namesVyxeos
Other namesCPX-351
AHFS/Drugs.comMonograph
License data
Pregnancy
category
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Daunorubicin/cytarabine is a fixed-dose combination medication used for the treatment of acute myeloid leukemia.[2][3] It contains the liposomal bound daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor.[2]

Medical uses[edit]

Daunorubicin/cytarabine is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in people aged one year of age and older.[2][4][5][6][7]

References[edit]

  1. ^ a b "Vyxeos APMDS". Therapeutic Goods Administration (TGA). 15 June 2022. Archived from the original on 18 June 2022. Retrieved 18 June 2022.
  2. ^ a b c d "Vyxeos (- daunorubicin and cytarabine liposome injection, powder, lyophilized, for suspension". DailyMed. 13 April 2021. Archived from the original on 29 March 2021. Retrieved 18 June 2022.
  3. ^ Molica, Matteo; Perrone, Salvatore; Mazzone, Carla; Cesini, Laura; Canichella, Martina; de Fabritiis, Paolo (January 2022). "CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML". Cancers. 14 (12): 2843. doi:10.3390/cancers14122843. ISSN 2072-6694. PMC 9221356. PMID 35740508.
  4. ^ "Vyxeos (cytarabine/daunorubicin liposomal) dosing, indications, interactions, adverse effects, and more". Medscape. Archived from the original on 15 August 2017. Retrieved 19 March 2019.
  5. ^ "Vyxeos (cytarabine and daunorubicin) FDA Approval History". Drugs.com. Archived from the original on 11 April 2019. Retrieved 30 December 2018.
  6. ^ Chen EC, Fathi AT, Brunner AM (2018). "Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML". OncoTargets and Therapy. 11: 3425–3434. doi:10.2147/OTT.S141212. PMC 6003284. PMID 29928134.
  7. ^ Cafaro A, Giannini MB, Silimbani P, Cangini D, Masini C, Ghelli Luserna Di Rorà A, et al. (October 2020). "CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia". Minerva Medica. 111 (5): 455–466. doi:10.23736/S0026-4806.20.07017-2. PMID 32955826. S2CID 221842680.

External links[edit]